| Tuesday, June 24, 2025 Abstract Session 32 – CRS – biologics 4 ROOM 9 (G6) | Level +1 11:35h – 12:50h ABSTRACTS |
| Chair 1: Sven Becker |
| Chair 2: Joaquim Mullol |
| 4107 – Mepolizumab Is Efficacious in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With One or Multiple Prior Nasal Polyps (NP) Surgeries: SYNAPSE Outcomes |
| Mullol Joaquim |
| 4115 – Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: Evidence from the European CRS Outcome Registry (CHRINOSOR) |
| Mortuaire Geoffrey |
| 4163 – Twice-Yearly Depemokimab Demonstrates Enhanced SNOT-22 Outcomes Among Patients with Baseline SNOT-22 Score ≥40 in the Phase III ANCHOR-1/2 Studies |
| Keles Turel Nesil |
| 4156 – Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab |
| Howarth Peter |
| 4131 – One year mepolizumad outcomes in severe, uncontrolled CRSwNP: A real-life study |
| Corbò Marco |
| 4167 – Characterization of PAPP-A patterns in chronic rhinosinusitis (CRS) |
| Ennahal Afaf |
| 3858 – Real-world effectiveness of mepolizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Findings from CHRINOSOR |
| Seys Sven |
| 4184 – Significance of olfactory function in terms of quality of life in CRSwNP patients treated with dupilumab. Real life study. |
| Ludányi Kristóf |
